Novo Nordisk has seen a steep reset in its share price over the past few years, which puts a spotlight on whether the current market value still lines up with what the business earns. With earnings at the centre of most long term theses on the stock, the question is how well the present price reflects that profit stream today. Over the past 3 years the share price has fallen about 60%, which makes the link between Novo Nordisk's current valuation and its earnings power a much more pressing topic for investors. The ongoing DKK 15b share repurchase programme, including the buyback of 37,849,179 B shares by 9 October 2026, can reshape per share earnings and therefore changes how investors might think about what a fair multiple looks like.
Головну думку ми показуємо публічно. Створіть безкоштовний акаунт, щоб читати повну статтю, зберігати її, обговорювати та поєднувати з ринковим і OSINT-контекстом.